The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to
Valsartan and Olmesartan(reference group) in patients with mild to moderate essential
hypertension. Patients have 2 weeks of placebo run-in and wash out period, 2 weeks of taking
required dose and 4 weeks of taking double dose.